RecruitingNCT05719545

A Cohort of Patients Undergoing Percutaneous Coronary Intervention

A Longitudinal Cohort of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Sponsor

Su Guohai

Enrollment

10,000 participants

Start Date

Dec 1, 2021

Study Type

OBSERVATIONAL

Conditions

Acute Coronary Syndrome Myocardial Infarction Percutaneous Coronary Intervention Unstable Angina

Summary

To investigate the risk factors involved in the occurrence and prognosis of the patients with acute coronary syndrome, patients undergoing percutaneous coronary intervention will be recruited and followed up for at least 2 years.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with acute coronary syndrome, myocardial infarction, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Jinan Central Hospital

Jinan, Shandong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05719545

Related Trials

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565103 locations

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

NCT072582901 location

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

NCT046951061 location

Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS

NCT060141129 locations

Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis

NCT054735206 locations